CN113786457A - Eye ointment for relieving visual fatigue - Google Patents
Eye ointment for relieving visual fatigue Download PDFInfo
- Publication number
- CN113786457A CN113786457A CN202111028067.2A CN202111028067A CN113786457A CN 113786457 A CN113786457 A CN 113786457A CN 202111028067 A CN202111028067 A CN 202111028067A CN 113786457 A CN113786457 A CN 113786457A
- Authority
- CN
- China
- Prior art keywords
- parts
- seed
- dendrobium
- eye ointment
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 25
- 239000003885 eye ointment Substances 0.000 title claims abstract description 23
- 241001523681 Dendrobium Species 0.000 claims abstract description 30
- 229940099259 vaseline Drugs 0.000 claims abstract description 15
- 239000000022 bacteriostatic agent Substances 0.000 claims abstract description 11
- 239000007951 isotonicity adjuster Substances 0.000 claims abstract description 11
- 229940111630 tea tree oil Drugs 0.000 claims abstract description 11
- 239000010677 tea tree oil Substances 0.000 claims abstract description 11
- 239000002562 thickening agent Substances 0.000 claims abstract description 11
- 240000008365 Celosia argentea Species 0.000 claims abstract description 10
- 235000000722 Celosia argentea Nutrition 0.000 claims abstract description 10
- 241000195955 Equisetum hyemale Species 0.000 claims abstract description 10
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 10
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 10
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 10
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 10
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 10
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 10
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 10
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 10
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 10
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 10
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 10
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 10
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 10
- 235000008113 selfheal Nutrition 0.000 claims abstract description 10
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 7
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 12
- 239000003480 eluent Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000007605 air drying Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000003958 fumigation Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 240000002948 Ophiopogon intermedius Species 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 239000000155 melt Substances 0.000 claims description 3
- 230000010355 oscillation Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 6
- 230000004438 eyesight Effects 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 abstract description 3
- 239000000835 fiber Substances 0.000 abstract description 2
- 210000001328 optic nerve Anatomy 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000000007 visual effect Effects 0.000 abstract 1
- 238000001467 acupuncture Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008589 Cortex Fraxini Substances 0.000 description 1
- RYAHJFGVOCZDEI-UFFNCVEVSA-N Dendrobine Chemical compound C([C@H]1CC[C@@H]2[C@@]31C)N(C)[C@@H]3[C@H]1[C@@H](C(C)C)[C@@H]2C(=O)O1 RYAHJFGVOCZDEI-UFFNCVEVSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000028571 Occupational disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- RYAHJFGVOCZDEI-CZKZLRAZSA-N dendrobine Natural products O=C1O[C@@H]2[C@H](C(C)C)[C@H]1[C@H]1[C@@]3(C)[C@@H]2N(C)C[C@H]3CC1 RYAHJFGVOCZDEI-CZKZLRAZSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
- A61K35/06—Mineral oils, e.g. paraffinic oils or aromatic oils based on aromatic hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an eye ointment for relieving visual fatigue. The components by weight portion are as follows: 5-15 parts of cassia seed, 5-10 parts of ash bark, 30-50 parts of vaseline, 15-20 parts of wolfberry fruit, 10-18 parts of scutellaria baicalensis, 5-15 parts of dendrobium flower, 10-20 parts of radix ophiopogonis, 10-20 parts of scouring rush, 10-20 parts of feather cockscomb seed, 10-20 parts of plantain seed, 10-20 parts of mint, 10-20 parts of selfheal, 1-2 parts of tea tree oil, 1-3 parts of bacteriostatic agent, 2-5 parts of regulator, 1-5 parts of isotonic agent and 5-10 parts of thickening agent. The main component of the eye ointment prepared by the invention is dendrobium, which is beneficial to the recovery of the functions of damaged visual cells and optic nerve fibers, and has the effects of improving eyesight and curing eye fatigue.
Description
Technical Field
The invention relates to an eye ointment for relieving visual fatigue.
Background
At present, office workers sit at the desk for nearly 8 hours every day in nine nights and five days, stare at the computer screen and keep still, so that the eye fatigue, dry eyes and visual deterioration become most of white-collar occupational diseases. With the rapid development of the information era and the acceleration of the pace of life, more than these office workers, especially the video display terminals such as computers, televisions, game machines and the like have gradually merged into the work, study and life of people, and the asthenopia has become the common disease of ophthalmology at present, and seriously affects the life of people.
Asthenopia is not an independent disease but a group of fatigue syndromes due to various causes. At present, the treatment methods comprise physical therapies such as prism correction, surgical treatment, acupuncture and moxibustion and the like, and some chemical medicines such as nerve nutritional agents, tranquilizers and the like are adopted, and the treatment is carried out aiming at symptoms, so that the fundamental treatment aim cannot be achieved. Researches find that the eye health care product for relieving and preventing the visual fatigue is obvious in curative effect when natural medicines and traditional Chinese medicines are used for treating the visual fatigue, but at present, no good eye health care product for relieving and preventing the visual fatigue is available.
Disclosure of Invention
Aiming at the problems in the prior art, the invention aims to provide a technical scheme of an eye ointment for relieving visual fatigue.
The eye ointment for relieving the visual fatigue is characterized by comprising the following components in parts by weight: 5-15 parts of cassia seed, 5-10 parts of ash bark, 30-50 parts of vaseline, 15-20 parts of wolfberry fruit, 10-18 parts of scutellaria baicalensis, 5-15 parts of dendrobium flower, 10-20 parts of radix ophiopogonis, 10-20 parts of scouring rush, 10-20 parts of feather cockscomb seed, 10-20 parts of plantain seed, 10-20 parts of mint, 10-20 parts of selfheal, 1-2 parts of tea tree oil, 1-3 parts of bacteriostatic agent, 2-5 parts of regulator, 1-5 parts of isotonic agent and 5-10 parts of thickening agent.
The eye ointment for relieving the visual fatigue is characterized by comprising the following components in parts by weight: 10 parts of cassia seed, 8 parts of ash bark, 40 parts of vaseline, 18 parts of wolfberry fruit, 14 parts of scutellaria baicalensis, 10 parts of dendrobium flower, 15 parts of dwarf lilyturf tuber, 15 parts of scouring rush, 15 parts of feather cockscomb seed, 15 parts of plantain seed, 15 parts of mint, 15 parts of selfheal, 1.5 parts of tea tree oil, 2 parts of bacteriostatic agent, 3.5 parts of regulator, 3 parts of isotonic agent and 8 parts of thickening agent.
The preparation method of the eye ointment for relieving the visual fatigue comprises the following specific preparation steps:
1) 5-15 parts of semen cassiae, 5-10 parts of ash bark, 15-20 parts of wolfberry fruit, 10-18 parts of scutellaria baicalensis, 10-20 parts of radix ophiopogonis, 10-20 parts of scouring rush, 10-20 parts of feather cockscomb seed, 10-20 parts of plantain seed, 10-20 parts of mint and 10-20 parts of selfheal, 50-100 parts of purified water is added after mixing for decoction, the obtained medicine juice is eluted by 15% ethanol, 20-30 parts of eluent is collected and then eluted by 40% ethanol, 20-40 parts of eluent is collected, the ethanol is recovered under reduced pressure after the two eluents are mixed, and the filtrate is taken for later use after filtration;
2) taking a container, wherein a layer of latticed baffle is arranged in the container, the distance between the baffle and the bottom is 10-15cm, 5-15 parts of dendrobium flowers are taken, the dendrobium flowers are laid on the baffle, the thickness of the dendrobium flowers is 2-5cm, the bottom is filled with the filtrate obtained in the step 1), the pressure in the container is reduced to 3.5Kpa, the container is sealed and then heated to 30-40 ℃, and the fumigation is carried out for 10-30 min;
3) taking out the fumigated dendrobium flowers, airing and crushing the dendrobium flowers to 400-mesh and 600-mesh particles for later use;
4) mixing and stirring 30-50 parts of vaseline and 1-2 parts of tea tree oil, adding into 5-10 parts of purified water, heating to 70-90 ℃, sequentially adding the particles, the bacteriostatic agent 1-3 parts, the regulator 2-5 parts, the isotonic agent 1-5 parts and the thickening agent 5-10 parts in the step 3) after the vaseline melts to be in a viscous state, carrying out oscillation stirring at the rotation speed of 100 and 300r/min, and naturally cooling and air-drying after the stirring is finished to obtain the eye ointment.
The main component of the eye ointment prepared by the invention is dendrobium, dendrobine and dendrobe polysaccharide contained in the dendrobium have the effects of inhibiting and correcting enzyme activity abnormal change caused by galactose deficiency, preventing the proportion imbalance of total esters of crystalline lens and total cholesterol caused by galactose deficiency, improving circulatory disturbance, improving metabolic dysfunction caused by cell ischemia and hypoxia, enhancing the metabolic capability of local tissues, promoting nerve fibers which are not completely out of function and in a suppressed state to play a compensation function through repair, helping the recovery of damaged cells and optic nerve fibers, and playing a role in improving vision and curing eye fatigue.
Detailed Description
The eye ointment for relieving the visual fatigue comprises the following components in parts by weight: 5-15 parts of cassia seed, 5-10 parts of ash bark, 30-50 parts of vaseline, 15-20 parts of wolfberry fruit, 10-18 parts of scutellaria baicalensis, 5-15 parts of dendrobium flower, 10-20 parts of radix ophiopogonis, 10-20 parts of scouring rush, 10-20 parts of feather cockscomb seed, 10-20 parts of plantain seed, 10-20 parts of mint, 10-20 parts of selfheal, 1-2 parts of tea tree oil, 1-3 parts of bacteriostatic agent, 2-5 parts of regulator, 1-5 parts of isotonic agent and 5-10 parts of thickening agent.
A preparation method of an eye ointment for relieving visual fatigue comprises the following specific preparation steps:
1) 5-15 parts of semen cassiae, 5-10 parts of ash bark, 15-20 parts of wolfberry fruit, 10-18 parts of scutellaria baicalensis, 10-20 parts of radix ophiopogonis, 10-20 parts of scouring rush, 10-20 parts of feather cockscomb seed, 10-20 parts of plantain seed, 10-20 parts of mint and 10-20 parts of selfheal, 50-100 parts of purified water is added after mixing for decoction, the obtained medicine juice is eluted by 15% ethanol, 20-30 parts of eluent is collected and then eluted by 40% ethanol, 20-40 parts of eluent is collected, the ethanol is recovered under reduced pressure after the two eluents are mixed, and the filtrate is taken for later use after filtration;
2) taking a container, wherein a layer of latticed baffle is arranged in the container, the distance between the baffle and the bottom is 10-15cm, 5-15 parts of dendrobium flowers are taken, the dendrobium flowers are laid on the baffle, the thickness of the dendrobium flowers is 2-5cm, the bottom is filled with the filtrate obtained in the step 1), the pressure in the container is reduced to 3.5Kpa, the container is sealed and then heated to 30-40 ℃, and the fumigation is carried out for 10-30 min;
3) taking out the fumigated dendrobium flowers, airing and crushing the dendrobium flowers to 400-mesh and 600-mesh particles for later use;
4) mixing and stirring 30-50 parts of vaseline and 1-2 parts of tea tree oil, adding into 5-10 parts of purified water, heating to 70-90 ℃, sequentially adding the particles, the bacteriostatic agent 1-3 parts, the regulator 2-5 parts, the isotonic agent 1-5 parts and the thickening agent 5-10 parts in the step 3) after the vaseline melts to be in a viscous state, carrying out oscillation stirring at the rotation speed of 100 and 300r/min, and naturally cooling and air-drying after the stirring is finished to obtain the eye ointment.
Example 1
The components by weight portion are as follows: 10 parts of cassia seed, 8 parts of ash bark, 40 parts of vaseline, 18 parts of wolfberry fruit, 14 parts of scutellaria baicalensis, 10 parts of dendrobium flower, 15 parts of dwarf lilyturf tuber, 15 parts of scouring rush, 15 parts of feather cockscomb seed, 15 parts of plantain seed, 15 parts of mint, 15 parts of selfheal, 1.5 parts of tea tree oil, 2 parts of bacteriostatic agent, 3.5 parts of regulator, 3 parts of isotonic agent and 8 parts of thickening agent.
A preparation method of an eye ointment for relieving visual fatigue comprises the following specific preparation steps:
1) mixing 10 parts of semen Cassiae, 8 parts of cortex Fraxini, 18 parts of fructus Lycii, 14 parts of radix Scutellariae, 10 parts of herba Dendrobii flower, 15 parts of radix Ophiopogonis, 15 parts of herba Equiseti hiemalis, 15 parts of semen Celosiae, 15 parts of semen plantaginis, 15 parts of herba Menthae and 15 parts of Spica Prunellae, adding 50-100 parts of purified water, decocting, eluting the obtained medicinal liquid with 15% ethanol, collecting 20-30 parts of eluate, eluting with 40% ethanol, collecting 20-40 parts of eluate, mixing the eluates, recovering ethanol under reduced pressure, filtering, and collecting filtrate;
2) taking a container, wherein a layer of latticed baffle is arranged in the container, the distance between the baffle and the bottom is 10-15cm, 5-15 parts of dendrobium flowers are taken, the dendrobium flowers are laid on the baffle, the thickness of the dendrobium flowers is 2-5cm, the bottom is filled with the filtrate obtained in the step 1), the pressure in the container is reduced to 3.5Kpa, the container is sealed and then heated to 30-40 ℃, and the fumigation is carried out for 10-30 min;
3) taking out the fumigated dendrobium flowers, airing and crushing the dendrobium flowers to 400-mesh and 600-mesh particles for later use;
4) taking 40 parts of vaseline and 1.5 parts of tea tree oil, mixing and stirring, adding 5-10 parts of purified water, heating at 70-90 ℃, adding the particles, 2 parts of bacteriostatic agent, 3.5 parts of regulator, 3 parts of isotonic agent and 8 parts of thickener in the step 3) in sequence after the vaseline is melted into a viscous state, oscillating and stirring at the rotation speed of 100 and 300r/min, and naturally cooling and air-drying after stirring to obtain the eye ointment.
Experimental example: 146 myopic patients were randomly selected and subjected to clinical trials, with patients between 10-50 years of age and an average age of 28 years, and patients were divided into 3 groups, experimental, control and blank. The patients in the experimental group applied the eye ointment provided in example 1 to eight acupuncture points around the eyes for massage, twice a day, once in the morning and at night; the control group used artificial tear eye drop twice a day, and was dropped once in the morning and evening; the eight acupoints around the eyes of the patients in the blank group are massaged by eye exercises twice a day, once in the morning and at night, and the conditions of the patients are observed after one week, wherein the conditions are as follows:
the vision of 48 patients in the experimental group is improved, and the vision of 24 patients is not changed and the condition of vision decline is not generated; of them, 56 people had no eye fatigue, and 17 people had improved eye fatigue, and only 1 person had no effect. Compared with a control group and a blank group, the eye ointment has obvious effect, so that the eye ointment provided by the invention has the functions of curing eye fatigue and improving eyesight.
Claims (3)
1. The eye ointment for relieving the visual fatigue is characterized by comprising the following components in parts by weight: 5-15 parts of cassia seed, 5-10 parts of ash bark, 30-50 parts of vaseline, 15-20 parts of wolfberry fruit, 10-18 parts of scutellaria baicalensis, 5-15 parts of dendrobium flower, 10-20 parts of radix ophiopogonis, 10-20 parts of scouring rush, 10-20 parts of feather cockscomb seed, 10-20 parts of plantain seed, 10-20 parts of mint, 10-20 parts of selfheal, 1-2 parts of tea tree oil, 1-3 parts of bacteriostatic agent, 2-5 parts of regulator, 1-5 parts of isotonic agent and 5-10 parts of thickening agent.
2. The eye ointment for relieving visual fatigue as claimed in claim 1, which is characterized by comprising the following components in parts by weight: 10 parts of cassia seed, 8 parts of ash bark, 40 parts of vaseline, 18 parts of wolfberry fruit, 14 parts of scutellaria baicalensis, 10 parts of dendrobium flower, 15 parts of dwarf lilyturf tuber, 15 parts of scouring rush, 15 parts of feather cockscomb seed, 15 parts of plantain seed, 15 parts of mint, 15 parts of selfheal, 1.5 parts of tea tree oil, 2 parts of bacteriostatic agent, 3.5 parts of regulator, 3 parts of isotonic agent and 8 parts of thickening agent.
3. The preparation method of the eye ointment for relieving visual fatigue as claimed in claim 1, which comprises the following steps:
1) 5-15 parts of semen cassiae, 5-10 parts of ash bark, 15-20 parts of wolfberry fruit, 10-18 parts of scutellaria baicalensis, 10-20 parts of radix ophiopogonis, 10-20 parts of scouring rush, 10-20 parts of feather cockscomb seed, 10-20 parts of plantain seed, 10-20 parts of mint and 10-20 parts of selfheal, 50-100 parts of purified water is added after mixing for decoction, the obtained medicine juice is eluted by 15% ethanol, 20-30 parts of eluent is collected and then eluted by 40% ethanol, 20-40 parts of eluent is collected, the ethanol is recovered under reduced pressure after the two eluents are mixed, and the filtrate is taken for later use after filtration;
2) taking a container, wherein a layer of latticed baffle is arranged in the container, the distance between the baffle and the bottom is 10-15cm, 5-15 parts of dendrobium flowers are taken, the dendrobium flowers are laid on the baffle, the thickness of the dendrobium flowers is 2-5cm, the bottom is filled with the filtrate obtained in the step 1), the pressure in the container is reduced to 3.5Kpa, the container is sealed and then heated to 30-40 ℃, and the fumigation is carried out for 10-30 min;
3) taking out the fumigated dendrobium flowers, airing and crushing the dendrobium flowers to 400-mesh and 600-mesh particles for later use;
4) mixing and stirring 30-50 parts of vaseline and 1-2 parts of tea tree oil, adding into 5-10 parts of purified water, heating to 70-90 ℃, sequentially adding the particles, the bacteriostatic agent 1-3 parts, the regulator 2-5 parts, the isotonic agent 1-5 parts and the thickening agent 5-10 parts in the step 3) after the vaseline melts to be in a viscous state, carrying out oscillation stirring at the rotation speed of 100 and 300r/min, and naturally cooling and air-drying after the stirring is finished to obtain the eye ointment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111028067.2A CN113786457A (en) | 2021-09-02 | 2021-09-02 | Eye ointment for relieving visual fatigue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111028067.2A CN113786457A (en) | 2021-09-02 | 2021-09-02 | Eye ointment for relieving visual fatigue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113786457A true CN113786457A (en) | 2021-12-14 |
Family
ID=79182559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111028067.2A Pending CN113786457A (en) | 2021-09-02 | 2021-09-02 | Eye ointment for relieving visual fatigue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113786457A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116327846B (en) * | 2023-05-15 | 2023-11-03 | 普润德百目通(北京)科技有限公司 | Traditional Chinese medicine eye ointment for nourishing blood and improving eyesight and preparation method thereof |
-
2021
- 2021-09-02 CN CN202111028067.2A patent/CN113786457A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116327846B (en) * | 2023-05-15 | 2023-11-03 | 普润德百目通(北京)科技有限公司 | Traditional Chinese medicine eye ointment for nourishing blood and improving eyesight and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102139038A (en) | Chinese herbal preparation for treating eye diseases | |
| CN101380395A (en) | Traditional Chinese medicine composition for preventing and treating ophthalmic diseases and preparation method thereof | |
| CN102631558B (en) | Medicament for treating eye disease and preparation method of medicament | |
| CN103393969A (en) | Eye drop used for releasing eye fatigue and preparation method thereof | |
| CN100364593C (en) | Oral liquid for promoting eyesight and protecting eye | |
| CN110559364A (en) | Formula of novel eye ointment | |
| CN113786457A (en) | Eye ointment for relieving visual fatigue | |
| CN108208835A (en) | A kind of black, red matrimony vine compound eyeshield oral liquid and preparation method thereof | |
| CN112022938B (en) | Hydrogel eye patch for relieving asthenopia and preventing myopia and preparation method thereof | |
| CN111214583A (en) | Eye protection medicine bag capable of relieving visual fatigue | |
| CN111450170A (en) | Eyesight-improving and eye-protecting composition for children and application and preparation method thereof | |
| CN101284048A (en) | Formulations for effectively improving hypometropia, asthenopia, cataract, eyeground pathological changes | |
| CN102462753B (en) | Traditional Chinese medicine composition capable of treating cervical vertigo and preparation method thereof | |
| CN111514190A (en) | A topical Chinese medicinal composition for improving eyesight, and its preparation method | |
| CN106728321A (en) | A kind of eye ointment and preparation method thereof | |
| CN104116774A (en) | Rhodiola rosea extract, extraction method as well as application and product thereof in treatment/prevention of eye disease | |
| CN112891439A (en) | Compound pipewort liquid | |
| CN113350430A (en) | Chinese herbal medicine eye-nourishing eye-protecting liquid and preparation method thereof | |
| CN113425800A (en) | Traditional Chinese medicine composition for relieving visual fatigue and preparation method thereof | |
| CN1056292C (en) | Eyesight granule and its compounding process | |
| CN112451622A (en) | A preparation for treating myopia, amblyopia and astigmatism, and its preparation method | |
| CN111617160A (en) | A Chinese medicinal composition with immunity enhancing effect | |
| CN1272370A (en) | Eye ointment for curing myopia and its production process | |
| CN111450179A (en) | Eyesight improving and eye protecting composition and application and preparation method thereof | |
| CN1164426A (en) | Health-care eyeshade with medicinal lining |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |